Advertisement
Home »

Ravulizumab Effective in AQP4-Positive NMOSD

May 08, 2023

REFERENCES & ADDITIONAL READING

Pittock S. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial. Session S5.002, AAN 2023 Annual Meeting, 22–27 April, Boston, USA.

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement